ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/27/2025 07:25 PDT] ABVC Expected to Trade Up After Bullish Patterns Develop
• [05/06/2025 07:17 PDT] ABVC Expected to Trade Up After Bullish Patterns Develop
• [04/24/2025 07:34 PDT] ABVC Expected to Trade Up After Bullish Patterns Develop
• [04/16/2025 07:17 PDT] ABVC Expected to Trade Up After Bullish Patterns Develop
• [04/09/2025 07:19 PDT] ABVC Expected to Trade Up After Bullish Patterns Develop
• [04/07/2025 08:02 PDT] ABVC Expected to Trade Down After Bearish Patterns Develop
• [04/02/2025 07:08 PDT] ABVC Expected to Trade Up After Bullish Patterns Develop
• [04/01/2025 07:35 PDT] ABVC Expected to Trade Up After Bullish Patterns Develop